Synthesis and biologic activity of new side-chain-altered methotrexate and aminopterin analogs with dual inhibitory action against dihydrofolate reductase and folylpolyglutamate synthetase.
Replacement of the glutamic acid (Glu) moiety in methotrexate (MTX) and aminopterin (AMT) by 2-amino-4-phosphonobutyric acid (APBA) and ornithine (Orn) has been found to give analogs that retain the ability to inhibit dihydrofolate reductase (DHFR) while also displaying high activity against folylpolyglutamate synthetase (FPGS). One of these compounds, the Orn analog of AMT, is the most potent FPGS inhibitor we have found to date. A model to account for the fact that side-chain analogs containing a basic and those containing an acidic terminal group can both competitively inhibit FPGS is proposed. According to this model, binding may involve interaction of an acidic terminal group on the inhibitor with a positively charged active-site residue to which the gamma-carboxyl of the folate-antifolate substrate normally binds. It may also involve the interaction of a basic terminal group on the inhibitor with a different active-site residue which is negatively rather than positively charged and to which the alpha-amino group of the incoming Glu cosubstrate must bind before an amide bond to the gamma-carboxyl of the folate-antifolate can form. The 2 oppositely charged active-site residues assumed to take part in this binding are probably situated near each other and at approximately the same distance from the pteridine-binding site. The ability of compounds to inhibit both DHFR and FPGS makes it possible in principle for such compounds to kill cells via a "self-potentiation" mechanism in which inhibition of tetrahydrofolate synthesis is complemented by interference with the subsequent conversion of tetrahydrofolates to their polyglutamate conjugates. Possible exploitation of this mechanism to overcome MTX resistance is considered.
Rosowsky
A
A
Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Boston, MA 02115.
Moran
R G
RG
Freisheim
J H
JH
Bader
H
H
Forsch
R A
RA
Solan
V C
VC
D000613:Aminobutyrates; D000630:Aminopterin / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002455:Cell Division / Q000187:drug effects; D005493:Folic Acid Antagonists / Q000138:chemical synthesis; D006131:Growth Inhibitors; D007939:Leukemia L1210 / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D008727:Methotrexate / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D009952:Ornithine / Q000031:analogs & derivatives; D010453:Peptide Synthases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000613:Aminobutyrates; D005493:Folic Acid Antagonists; D006131:Growth Inhibitors; D009952:Ornithine; D010453:Peptide Synthases; C023103:folylpolyglutamate synthetase; C012729:2-amino-4-phosphonobutyric acid; D000630:Aminopterin; D008727:Methotrexate